Last reviewed · How we verify
Chlorhexidine, Mupirocin
This combination of chlorhexidine and mupirocin works by disrupting bacterial cell membranes and inhibiting bacterial protein synthesis to prevent and treat skin infections.
This combination of chlorhexidine and mupirocin works by disrupting bacterial cell membranes and inhibiting bacterial protein synthesis to prevent and treat skin infections. Used for Skin and soft tissue infection prevention and treatment, Surgical site infection prophylaxis, Wound care and management.
At a glance
| Generic name | Chlorhexidine, Mupirocin |
|---|---|
| Also known as | Hibiclens, Bactroban |
| Sponsor | University of Tennessee |
| Drug class | Topical antimicrobial combination |
| Target | Bacterial cell membrane (chlorhexidine); isoleucyl-tRNA synthetase (mupirocin) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infection Prevention |
| Phase | FDA-approved |
Mechanism of action
Chlorhexidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, while mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Together, they provide synergistic antimicrobial activity against a wide range of gram-positive and gram-negative bacteria, making them effective for topical infection prevention and treatment.
Approved indications
- Skin and soft tissue infection prevention and treatment
- Surgical site infection prophylaxis
- Wound care and management
Common side effects
- Local skin irritation
- Contact dermatitis
- Erythema
- Pruritus
Key clinical trials
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Staph Household Intervention for Eradication (SHINE) (PHASE4)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
- Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients
- Staph Intervention for Effective Local Defense (PHASE4)
- Bacterial Decolonization Within Dyads (NA)
- The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorhexidine, Mupirocin CI brief — competitive landscape report
- Chlorhexidine, Mupirocin updates RSS · CI watch RSS
- University of Tennessee portfolio CI